Key facts
- CytoReason’s last known valuation is $159.8M.
- It has raised $123.0M; the latest was Later Stage VC ($80.0M) in Jul 2024.
- Notable investors include Nvidia, OurCrowd, Asymmetry Ventures, Astarc Ventures, IM Infinity Innonation — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for CytoReason
- ·The full record, as it builds
Funding rounds
No funding rounds for CytoReason are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CytoReason
Provider of cell-based models and data analysis services intended to develop a computational model of the human body that simulates human disease on a cellular level. The company's platform uses a proprietary data and machine learning (ML) model to reconstruct cellular information from bulk tissue, train an immune-specific engine and integrate multi-omics data that generates a mechanistic understanding of the immune system, enabling pharmaceutical companies to discover and develop the right therapies for the right patients, at the right time.
- Sector
- Healthcare
- HQ
- Tel Aviv, Israel
- Founded
- 2016
- Employees
- 129
- Website
- cytoreason.com/
- Ownership
- Privately Held (backing)
CytoReason doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CytoReason shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CytoReason in its N-PORT filings yet. We sweep new filings monthly.